Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Purdue Targets Palladone Phased Launch Start For First Half Of 2005

This article was originally published in The Pink Sheet Daily

Executive Summary

For the first 18 months of launch, Purdue will limit promotion to experienced opioid-prescribing physicians to assess whether the appropriate patients are receiving extended-release hydromorphone.

You may also be interested in...



Compromise House Rx Abuse Monitoring Bill Moves Away From National Database

The bill would establish HHS grants for state databases. The compromise bill could be ready for House floor action in days, committee members say.

Compromise House Rx Abuse Monitoring Bill Moves Away From National Database

The bill would establish HHS grants for state databases. The compromise bill could be ready for House floor action in days, committee members say.

Palladone Risk Management Program Includes Patient Medication Guide

Purdue's Palladone (extended-release hydromophone) risk management plan includes a patient medication guide which stresses that the product is only suitable for opioid-tolerant patients

Topics

UsernamePublicRestriction

Register

SC142962

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel